With the discovery of TNFR2 signaling pathway polymorphisms and mutations in SS and long prior course of diverse therapeutic interventions, it is vital to show that TNFR2 antagonistic antibodies have the capacity to kill TNFR2+ Tregs and TNFR2 oncogene-expressing tumor cells. The gene discussed is TNFRSF1B; the disease is synovial sarcoma.